연구동향 분석

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

옥찬영 유신혜 김범석 김미소 김태민 전윤경 김동완 정두현 허대석 2019년

논문상세정보
인용/피인용
' Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Anaplastic lymphoma kinase
  • Crizotinib
  • Proportional hazards models
  • disease-free survival
  • lung neoplasms
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
159 0

0.0%

' Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer' 의 참고문헌

  • When progressive disease does not mean treatment failure : reconsidering the criteria for progression
    Oxnard GR [2012]
  • Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib
    Park JH [2013]
  • Treating ALK-positive lung cancer : early successes and future challenges
    Camidge DR [2012]
  • The"lazarus response"in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation
    Langer CJ [2009]
  • Results of a global phase II study with crizotinib in advanced ALK-positive nonsmall cell lung cancer (NSCLC)
    Kim DW [2012]
  • Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
    Riely GJ [2007]
  • Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment
    Kim ST [2010]
  • Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma : results from the European Thoracic Oncology Platform Lungscape Project
  • Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    김범석 [2014]
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  • New guidelines to evaluate the response to treatment in solid tumors
    Therasse P [2000]
  • Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib
    Wu KL [2015]
  • Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
    Soda M [2007]
  • Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer
    Kim S [2013]
  • Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
    Rikova K [2007]
  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer
    Solomon BJ [2014]
  • Final results of the large-scale multinational trial PROFILE 1005 : efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
    Blackhall F [2017]
  • Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations : importance of bone metastasis
    Fujimoto D [2014]
  • Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
    Politi K [2010]
  • EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
    Choi YL [2010]
  • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Shaw AT [2013]
  • Concomitant ALK translocation and EGFR mutation in lung cancer : a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor
    Won JK [2015]
  • Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases
    Costa DB [2015]
  • Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
    Yokouchi H [2007]
  • Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
    Ou SH [2014]
  • Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer
    Kwak EL [2010]
  • A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
    Florescu M [2008]